FAST NEWS: Legend Biotech Halts Trials for LB1901 CAR-T Therapy Drug
The latest: Legend Biotech Corp. (LEGN.US) announced that the Phase 1 clinical trial for its LB1901 drug has been put on hold. LB1901 is the company’s autologous chimeric antigen receptor…
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
